metastasis
The company has previously offered its liquid biopsy tests through an LDT model but sees the timing and the clinical niche as right for a regulatory bid in CSF testing.
Biocept Q4 Revenues Spike as COVID-19 Testing Continues to Soar, Core Cancer Tests Lag
The firm's fourth quarter revenues included $18.3 million in commercial test revenue, of which $17.6 million was attributable to COVID-19 tests.
Biocept Eyes Neuro-Oncology for Future Liquid Biopsy Growth as Testing Lags Amid COVID Pandemic
The company highlighted efforts to expand the use of its tests in the analysis of cerebrospinal fluid, an area in which research collaborations have begun to yield some data.
Paige Expects FDA-Cleared Image Viewer, Future AI Products to Expand Digital Pathology Adoption
The firm anticipates soon receiving FDA clearance for future products, including an AI-based prostate cancer detection system that received CE marking in 2019.
Foundation Medicine Shifts Focus to Early Cancer Detection With Lexent Bio Acquisition
Lexent's technology integrates low-pass whole-genome sequencing, fragmentomics, and DNA methylation to detect early stage disease.